MA43178A - Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci - Google Patents
Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ciInfo
- Publication number
- MA43178A MA43178A MA043178A MA43178A MA43178A MA 43178 A MA43178 A MA 43178A MA 043178 A MA043178 A MA 043178A MA 43178 A MA43178 A MA 43178A MA 43178 A MA43178 A MA 43178A
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- synthesis
- treatment
- drug conjugates
- epothilone analogues
- Prior art date
Links
- 238000000034 method Methods 0.000 title 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 229930013356 epothilone Natural products 0.000 title 1
- 150000003883 epothilone derivatives Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562242702P | 2015-10-16 | 2015-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43178A true MA43178A (fr) | 2018-09-12 |
Family
ID=58518025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043178A MA43178A (fr) | 2015-10-16 | 2016-10-14 | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10874646B2 (fr) |
| EP (1) | EP3371176A4 (fr) |
| JP (1) | JP2018534283A (fr) |
| CN (1) | CN108430996A (fr) |
| AU (1) | AU2016340093A1 (fr) |
| BR (1) | BR112018007673A2 (fr) |
| CA (1) | CA3002027A1 (fr) |
| MA (1) | MA43178A (fr) |
| MX (1) | MX2018004696A (fr) |
| WO (1) | WO2017066606A1 (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4045487B1 (fr) * | 2019-10-18 | 2025-02-12 | Fmc Corporation | Procédés de préparation d'acide 5-bromo-2-(3-chloro-pyridin-2-yl)-2 h-pyrazole-3-carboxylique |
| PL3976588T3 (pl) * | 2019-10-18 | 2023-08-21 | Fmc Corporation | Sposoby wytwarzania kwasu 5-bromo-2-(3-chloropirydyn-2-ylo)-2h- pirazolo-3-karboksylowego |
| AU2020366037A1 (en) * | 2019-10-18 | 2022-04-21 | Fmc Corporation | Methods for the preparation of 5-bromo-2-(3-chloro-pyridin-2-yl)-2H-pyrazole-3-carboxylic acid |
| WO2025078841A2 (fr) | 2023-10-11 | 2025-04-17 | Antikor Biopharma Limited | Anticorps, conjugués et leurs utilisations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
| US6380394B1 (en) * | 1996-12-13 | 2002-04-30 | The Scripps Research Institute | Epothilone analogs |
| US6380395B1 (en) | 1998-04-21 | 2002-04-30 | Bristol-Myers Squibb Company | 12, 13-cyclopropane epothilone derivatives |
| IL144370A0 (en) | 1999-02-11 | 2002-05-23 | Schering Ag | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals |
| AU772750C (en) | 1999-04-30 | 2005-02-24 | Schering Aktiengesellschaft | 6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations |
| CA2628227A1 (fr) | 2005-11-22 | 2007-05-31 | The Scripps Research Institute | Synthese chimique d'un epothilone tres puissant |
| PE20080102A1 (es) | 2006-05-25 | 2008-02-11 | Bristol Myers Squibb Co | Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos |
| AR061181A1 (es) * | 2006-05-25 | 2008-08-13 | Bristol Myers Squibb Co | Compuestos de aziridinil-epotilona |
| EP1930004A1 (fr) | 2006-12-08 | 2008-06-11 | Bayer Schering Pharma Aktiengesellschaft | Utilisation d'épothylones dans le traitement de l'ostéoporose et des maladies associées |
| EP2009114A1 (fr) * | 2007-06-29 | 2008-12-31 | Bayer Schering Pharma Aktiengesellschaft | Procédés, kits et composés pour déterminer la réactivité au traitement d'un trouble pathologique par épothilones |
| CN101519404B (zh) | 2008-02-29 | 2016-01-20 | 唐莉 | 15环噻酮衍生物及其制备方法与应用 |
| US20150314007A1 (en) * | 2012-12-21 | 2015-11-05 | Glykos Finland Oy | Linker-payload molecule conjugates |
| US20140323533A1 (en) * | 2013-04-29 | 2014-10-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
-
2016
- 2016-10-14 EP EP16856299.9A patent/EP3371176A4/fr not_active Withdrawn
- 2016-10-14 JP JP2018519372A patent/JP2018534283A/ja active Pending
- 2016-10-14 MA MA043178A patent/MA43178A/fr unknown
- 2016-10-14 MX MX2018004696A patent/MX2018004696A/es unknown
- 2016-10-14 US US15/768,800 patent/US10874646B2/en active Active
- 2016-10-14 BR BR112018007673A patent/BR112018007673A2/pt not_active Application Discontinuation
- 2016-10-14 WO PCT/US2016/057093 patent/WO2017066606A1/fr not_active Ceased
- 2016-10-14 CN CN201680074140.0A patent/CN108430996A/zh active Pending
- 2016-10-14 CA CA3002027A patent/CA3002027A1/fr active Pending
- 2016-10-14 AU AU2016340093A patent/AU2016340093A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018534283A (ja) | 2018-11-22 |
| US20190022069A1 (en) | 2019-01-24 |
| EP3371176A1 (fr) | 2018-09-12 |
| US10874646B2 (en) | 2020-12-29 |
| WO2017066606A1 (fr) | 2017-04-20 |
| AU2016340093A1 (en) | 2018-05-10 |
| CA3002027A1 (fr) | 2017-04-20 |
| CN108430996A (zh) | 2018-08-21 |
| EP3371176A4 (fr) | 2019-09-04 |
| BR112018007673A2 (pt) | 2018-11-06 |
| MX2018004696A (es) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46427A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3673947A4 (fr) | Cathéter et ensemble cathéter | |
| MA45270A (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3491026A4 (fr) | Anticorps humains, compositions pharmaceutiques et procédés | |
| EP3377042A4 (fr) | Substances et procédés de traitement de myopathies à base de titine et d'autres titinopathies | |
| EP3353841A4 (fr) | Procédé de préparation et d'application de composites de carbone-sélénium | |
| EP3313404A4 (fr) | Compositions thérapeutiques, associations et procédés d'utilisation | |
| EP3174874A4 (fr) | Sels de berbérine, sels ursodésoxycholiques et des combinaisons, des procédés de préparation et d'application correspondants | |
| EP3325017A4 (fr) | Compositions d'oligonucléotides et procédés associés | |
| EP3386484A4 (fr) | Compositions et procédés permettant d'administrer des agents thérapeutiques | |
| EP3320033A4 (fr) | Dépolymérisation de polytéréphtalate d'éthylène | |
| EP3717046A4 (fr) | Ensemble cathéter | |
| EP3443094A4 (fr) | Procédés de réduction de l'expression de c9orf72 | |
| EP3597258A4 (fr) | Ensemble cathéter | |
| EP3294865A4 (fr) | Procédés de production d'épimérases et d'alcaloïdes benzylisoquinoléine | |
| EP3341391A4 (fr) | Compositions et procédés pour le traitement de la douleur | |
| EP3628363A4 (fr) | Ensemble cathéter | |
| EP3331430A4 (fr) | Dispositifs et procédés de cartographie d'arythmie cardiaque | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| EP3661583A4 (fr) | Ensemble cathéter | |
| EP3395366A4 (fr) | Procédé de conception de médicament, médicament obtenu et application associée | |
| MA45326A (fr) | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation | |
| EP3417902A4 (fr) | Ensemble cathéter | |
| MA43178A (fr) | Analogues d'épothilone, procédés de synthèse, procédés de traitement, et conjugués médicamenteux de ceux-ci | |
| EP3402778A4 (fr) | Procédés et compositions médicamenteuses destinés au traitement de la maladie de lyme |